Therefore, Dkk-1 may serve as a new clinical indicator for RA: a biomarker of disease activity and bone erosion, as well as a marker of response to biological therapy with TNFα blockers and IL-1Ra. This evidence concerns the gene DKK1 and rheumatoid arthritis.